ReviewJournal of inflammation research2026
Interleukin-Mediated Macrophage Polarization in Allergic Rhinitis Inflammation: A Systematic Review.
Review in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Allergic rhinitis (AR) is driven by interleukin (IL) network dysregulation and imbalanced macrophage polarization. This systematic review summarizes the molecular mechanisms by which ILs regulate macrophage phenotypic switching in AR inflammation. Methods: We screened the PubMed and Embase databases from January 2010 to January 2026 to identify published studies. The search keywords used were as follows: ["interleukin" or "IL"], ["allergic rhinitis" or "AR"], ["macrophages"] and ["inflammation"]. A total of 223 peer-reviewed studies on human/animal models were included, and articles that did not meet the requirements were excluded. Results: Pro-inflammatory ILs (IL-4/IL-13, IL-1β/IL-6/IL-17A) promote pathogenic M1/M2a macrophage polarization via STAT6, NF-κB and NLRP3 pathways, aggravating inflammatory responses. Anti-inflammatory ILs (IL-10, IL-27) induce M2c polarization and restore immune balance through STAT3/STAT1 signaling. Targeted interventions (dupilumab, MCC950, chlorogenic acid) effectively reverse polarization imbalance and alleviate AR symptoms. Clinically, AR patients present disrupted IL ratios, M1/M2 imbalance and impaired nasal mucosal barriers. Conclusion: IL-mediated macrophage polarization is a core driver of AR inflammation. Targeting these regulatory pathways provides promising precision therapeutic strategies for AR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.